Evidence map›Paper›PMID 32036573›Full record

ReviewMolecular biology reports2020

TIRR: a potential front runner in HDR race-hypotheses and perspectives.

A A Anuchina, A V Lavrov, S A Smirnikhina

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Strategies for High-Efficiency Mutation Using the CRISPR/Cas System.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

A A AnuchinaLaboratory of Genome Editing, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, Russia, 115522. arinate@mail.ru.ORCID http://orcid.org/0000-0003-1820-5461
A V LavrovLaboratory of Genome Editing, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, Russia, 115522.ORCID http://orcid.org/0000-0003-4962-6947
S A SmirnikhinaLaboratory of Genome Editing, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, Russia, 115522.ORCID http://orcid.org/0000-0002-1558-3048
Research Centre for Medical Genetics · RU

Funding

Russian Science Foundation 17-75-20095
6 · The paper itself

Abstract

The majority of CRISPR-Cas9 methods for mutations correction are oriented on gene editing through homologous recombination that is normally restrained by non-homologous end joining (NHEJ). A recently identified protein TIRR can bind a 53BP1 protein, a key effector of NHEJ, and inhibit its recruitment to double-strand break loci. Several studies elucidated the molecular mechanisms of TIRR-53BP1 binding and established bidirectional role of TIRR in 53BP1 functions and stability. It was proved that overexpression of TIRR promotes the double-strand break repair through homologous recombination. All findings, which were described in the review, allow assuming TIRR as a suitable target for enhancing efficacy of genome editing through homology directed repair.

Indexed as

Recombinational DNA RepairAmino Acid MotifsAnimalsBinding SitesBiomarkersCarrier ProteinsChromatinDNA-Binding ProteinsDNA Breaks, Double-StrandedDNA RepairGene EditingHistonesHumansProtein Interaction Domains and MotifsProtein MultimerizationRNA-Binding ProteinsBiomarkersCarrier ProteinsChromatinDNA-Binding ProteinsHistonesNUDT16L1 protein, humanRNA-Binding ProteinsCRISPR-Cas9DSB repairHomology directed repairTIRRTudor-interacting repair regulator

Identifiers

PMID32036573
OpenAlexW3005525939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.